Clinical Trials Logo

Triple Negative Breast Neoplasms clinical trials

View clinical trials related to Triple Negative Breast Neoplasms.

Filter by:

NCT ID: NCT01695057 Withdrawn - Clinical trials for Stage IIIA Breast Cancer

Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer

Start date: October 2012
Phase: N/A
Study type: Interventional

This pilot clinical trial studies vorinostat before surgery in treating patients with triple-negative breast cancer. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving enzyme inhibitor therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed

NCT ID: NCT01333423 Withdrawn - Breast Cancer Clinical Trials

Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)

Start date: September 2012
Phase: Phase 1
Study type: Interventional

The goal of this clinical research study is to find the highest tolerable dose of seliciclib that can be given in combination with liposomal doxorubicin to patients with metastatic breast cancer.

NCT ID: NCT01292083 Withdrawn - Clinical trials for Stage IV Breast Cancer

Azacitidine in Treating Patients With Triple Negative Stage I-IV Invasive Breast Cancer That Can Be Removed By Surgery

Start date: January 2011
Phase: N/A
Study type: Interventional

This clinical trial studies azacitidine in treating patients with triple negative stage I-IV invasive breast cancer that can be removed by surgery. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.